Prognostic impact of chromogranin A in patients with acute heart failure
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Chromogranin A (CgA) levels have been reported to predict mortality in patients with heart failure. However, information on the prognostic value and clinical availability of CgA is limited. We compared the prognostic value of CgA to that of previously proven natriuretic peptide biomarkers in patients with acute heart failure. Methods: We retrospectively evaluated 272 patients (mean age, 68.5±15.6 years; 62.9% male) who underwent CgA test in the acute stage of heart failure hospitalization between June 2017 and June 2018. The median follow-up period was 348 days. Prognosis was assessed using the composite events of 1-year death and heart failure hospitalization. Results: In-hospital mortality rate during index admission was 7.0% (n=19). During the 1-year follow-up, a composite event rate was observed in 12.1% (n=33) of the patients. The areas under the receiver-operating characteristic curves for predicting 1-year adverse events were 0.737 and 0.697 for N-terminal pro-B-type natriuretic peptide (NT-proBNP) and CgA, respectively. During follow-up, patients with high CgA levels (>158 pmol/L) had worse outcomes than those with low CgA levels (≤158 pmol/L) (85.2% vs. 58.6%, p<0.001). When stratifying the patients into four subgroups based on CgA and NT-proBNP levels, patients with high NT-proBNP and high CgA had the worst outcome. CgA had an incremental prognostic value when added to the combination of NT-proBNP and clinically relevant risk factors. Conclusion: The prognostic power of CgA was comparable to that of NT-proBNP in patients with acute heart failure. The combination of CgA and NT-proBNP can improve prognosis prediction in these patients.
Abstract
Background: Chromogranin A (CgA) levels have been reported to predict mortality in patients with heart failure. However, information on the prognostic value and clinical availability of CgA is limited. We compared the prognostic value of CgA to that of previously proven natriuretic peptide biomarkers in patients with acute heart failure. Methods: We retrospectively evaluated 272 patients (mean age, 68.5±15.6 years; 62.9% male) who underwent CgA test in the acute stage of heart failure hospitalization between June 2017 and June 2018. The median follow-up period was 348 days. Prognosis was assessed using the composite events of 1-year death and heart failure hospitalization. Results: In-hospital mortality rate during index admission was 7.0% (n=19). During the 1-year follow-up, a composite event rate was observed in 12.1% (n=33) of the patients. The areas under the receiver-operating characteristic curves for predicting 1-year adverse events were 0.737 and 0.697 for N-terminal pro-B-type natriuretic peptide (NT-proBNP) and CgA, respectively. During follow-up, patients with high CgA levels (>158 pmol/L) had worse outcomes than those with low CgA levels (≤158 pmol/L) (85.2% vs. 58.6%, p<0.001). When stratifying the patients into four subgroups based on CgA and NT-proBNP levels, patients with high NT-proBNP and high CgA had the worst outcome. CgA had an incremental prognostic value when added to the combination of NT-proBNP and clinically relevant risk factors. Conclusion: The prognostic power of CgA was comparable to that of NT-proBNP in patients with acute heart failure. The combination of CgA and NT-proBNP can improve prognosis prediction in these patients.
참고문헌 (17)
- Benjamin EJ, "Heart Disease and Stroke Statistics-2019Update : A Report From the American Heart Association", Circulation, 139, pp.e56~e528 (2019)
- 이상언, "Clinical Characteristics and Outcome of Acute Heart Failure in Korea: Results from the Korean Acute Heart Failure Registry (KorAHF)", Korean Circulation Journal, 47(3), pp.341~353 (2017), 대한심장학회
- 안민수, "Prognostic Effect of Guideline-Directed Therapy Is More Noticeable Early in the Course of Heart Failure", Journal of Korean Medical Science, 34(17), pp.1~12 (2019), 대한의학회
- 김민석, "Korean Guidelines for Diagnosis and Management of Chronic Heart Failure", Korean Circulation Journal, 47(5), pp.555~643 (2017), 대한심장학회[DOI]
- 이주희, "KSHF Guidelines for the Management of Acute Heart Failure; Part II: Treatment of Acute Heart Failure", Korean Circulation Journal, 49(1), pp.22~45 (2019), 대한심장학회[DOI]
- 이주희, "KSHF Guidelines for the Management of Acute Heart Failure; Part I: Definition, Epidemiology and Diagnosis of Acute Heart Failure", Korean Circulation Journal, 49(1), pp.1~21 (2019), 대한심장학회[DOI]
- Cryer PE, "Plasma chromogranin A as a marker of sympathochromaffin activity in humans", Am J Physiol, 260(2 Pt 1), pp.E243~E246 (1991)
- Eriksson B, "Chromogranins : new sensitive markers for neuroendocrine tumors", Acta Oncol, 28, pp.325~329 (1989)
- Jansson AM, "Prognostic value of circulating chromogranin A levels in acute coronary syndromes", Eur Heart J, 30, pp.25~32 (2009)
- Ceconi C, "Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality", Eur Heart J, 23, pp.967~974 (2002)
- Ottesen AH, "Glycosylated chromogranin A in heart failure : implications for processing and cardiomyocyte calcium homeostasis", Circ Heart Fail, 10, pp.e003675~ (2017)
- Estensen ME, "Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction", Am Heart J, 152, pp.927~ (2006)
- Røsjø H, "Prognostic value of chromogranin A in chronic heart failure : data from the GISSI-Heart Failure trial", Eur J Heart Fail, 12, pp.549~556 (2010)
- Kantar M, "Plasma natriuretic peptides levels and echocardiographic findings in late subclinical anthracycline toxicity", Pediatr Hematol Oncol, 25, pp.723~733 (2008)
- Bhalla V, "B-type natriuretic peptide : the level and the drug : partners in the diagnosis of congestive heart failure", Congest Heart Fail, 10(1 Suppl 1), pp.3~27 (2004)
- Huang B, "Effect of B-type natriuretic peptide level on long-term outcome in patients with endstage heart failure", Am J Cardiol, 118, pp.383~388 (2016)
- 김민석, "KSHF Guidelines for the Management of Acute Heart Failure; Part III: Specific Management of Acute Heart Failure According to the Etiology and Co-morbidity", Korean Circulation Journal, 49(1), pp.46~68 (2019), 대한심장학회[DOI]